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intranasal administration of the 
antisecretory Peptide aF-16 reduces 
edema and improves cognitive 
Function Following Diffuse Traumatic 
Brain injury in the rat
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1 Unit for Neurosurgery, Department of Neuroscience, Uppsala University, Uppsala, Sweden, 2 Institute of Biomedicine, 
University of Gothenburg, Göteborg, Sweden, 3 Lantmännen AS Faktor AB, Stockholm, Sweden
A synthetic peptide with antisecretory activity, antisecretory factor (AF)-16, improves 
injury-related deficits in water and ion transport and decreases intracranial pressure after 
experimental cold lesion injury and encephalitis although its role in traumatic brain injury 
(TBI) is unknown. AF-16 or an inactive reference peptide was administrated intrana-
sally 30 min following midline fluid percussion injury (mFPI; n = 52), a model of diffuse 
mild-moderate TBI in rats. Sham-injured (n = 14) or naïve (n = 24) animals were used as 
controls. The rats survived for either 48 h or 15 days post-injury. At 48 h, the animals were 
tested in the Morris water maze (MWM) for memory function and their brains analyzed for 
cerebral edema. Here, mFPI-induced brain edema compared to sham or naïve controls 
that was significantly reduced by AF-16 treatment (p <  0.05) although MWM perfor-
mance was not altered. In the 15-day survival groups, the MWM learning and memory 
abilities as well as histological changes were analyzed. AF-16-treated brain- injured 
animals shortened both MWM latency and swim path in the learning trials (p < 0.05) 
and improved probe trial performance compared to brain-injured controls treated with 
the inactive reference peptide. A modest decrease by AF-16 on TBI-induced changes 
in hippocampal glial acidic fibrillary protein (GFAP) staining (p =  0.11) was observed. 
AF-16 treatment did not alter any other immunohistochemical analyses (degenerating 
neurons, beta-amyloid precursor protein (β-APP), and Olig2). In conclusion, intranasal 
AF-16-attenuated brain edema and enhanced visuospatial learning and memory fol-
lowing diffuse TBI in the rat. Intranasal administration early post-injury of a promising 
neuroprotective substance offers a novel treatment approach for TBI.
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inTrODUcTiOn
Traumatic brain injury (TBI) is a global health problem caused by e.g. motor vehicle accidents, 
falls, assaults, as well as work and sports injuries (1–4). Though TBI has a broad severity spectrum, 
even mild and moderate injuries frequently leave the patient with notable and persistent deficits. 
The initial brain injury occurring at time of impact is markedly exacerbated over hours, days, and 
TaBle 1 | number of animals in the different treatment groups.
naïve + scramble naïve + antisecretory factor (aF)-16 sham + scramble mFPi + scramble mFPi + aF-16
48-h survival 6 6 6 8 9
15-day survival 6 6 8 14 13
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months by complex secondary cascades (5, 6). In theory and 
as reported in many preclinical studies, these secondary injury 
factors should be amenable to pharmacological interventions 
resulting in improved clinical outcome. However, despite exten-
sive experimental research and many clinical trials, no pharma-
cological treatment has shown successful results in TBI patients 
(7). One of the most life-threatening secondary insults is cerebral 
edema, which can rapidly increase the intracranial pressure (ICP) 
to deleterious levels. The mechanisms behind the development of 
post-traumatic brain edema are complex, and both cytotoxic and 
vasogenic components contribute to the increase in brain water 
content (BWC) (7).
Diffuse axonal injury (DAI) was initially described in the 
1950s in patients who died early following severe TBI (8). Later, 
in the early 1980s, it was described as a separate clinicopathologi-
cal entity different from focal TBI in both the clinical setting (9) 
and in experimental models of acceleration injury TBI (10). A 
key pathophysiological event is the pathological deformation 
and stretching of axons after TBI resulting in dysfunctional 
axonal transport possibly leading to axonal transection. Injury to 
axons leads to brain network dysfunction, and the resulting DAI 
induces cognitive impairment and long-term sequelae (11, 12). 
Despite these severe clinical consequences, there is no beneficial 
pharmacological therapy available for DAI.
Antisecretory Factor (AF) is an endogenous protein with 
several pharmacological actions, most evidently preventing 
abnormal flow of fluid across cellular barriers and being anti-
inflammatory. To date, the most evaluated effects being the 
protection against diarrheal disease and intestinal inflamma-
tion (13). However, AF has not been shown to influence fluid 
distribution in normal tissue, nor exert any toxicity under normal 
conditions (14–17). A 16-peptide fragment, named AF-16, was 
developed as a pharmacological compound for intranasal admin-
istration, showing positive results on brain edema formation in 
both cold lesion injury (15, 16) and experimental encephalitis, in 
the latter study significantly improving survival due to reduced 
ICP without influencing the inflammatory response (18). Using 
the intranasal route of administration, AF-16 was observed 
to enter the brain and was detected in the cerebrospinal fluid 
[CSF (16)]. In the present study, we used a clinically relevant 
DAI model, the midline fluid percussion brain injury (mFPI), 
in rats and hypothesized that intranasal AF-16 could attenuate 
the traumatically induced cerebral edema, behavioral impair-
ment, and various TBI-induced histological factors. We choose a 
mild–moderate diffuse TBI model since this represents the most 
common injury type seen clinically. We focused our evaluation 
on the cognitive performance in the Morris Water Maze [MWM 
(19)]; in view of our experience that the commonly used tests of 
gross motor function are less sensitive in diffuse than in focal 
TBI models. Although systemic biomarkers may be important in 
prognosis, injury characterization and monitoring in clinical TBI 
(20, 21), this approach would require a much larger study using 
multiple time points and study groups. Instead, we focused our 
histological outcome on aspects of cell death, axonal and white 
matter injury, and astrogliosis known to be present in the mFPI 
model. Our results show that the brain edema was attenuated at 
48 h and the visuospatial learning performance was enhanced at 
least 15 days post-injury without significantly influencing histo-
logical outcome measures. These results suggest that AF-16 is a 
promising neuroprotective treatment of TBI and that intranasal 
administration is an attractive alternative route for the delivery of 
potentially beneficial pharmacological compounds to the injured 
brain.
MaTerials anD MeThODs
animals
The animal experiments were approved by the Uppsala County 
Animal Ethics board and followed the rules and regulations of the 
Swedish Agricultural Board. All evaluations were performed by a 
researcher blinded to the treatment status of each animal.
Male Sprague-Dawley rats (350–400 g, n = 90) were used; 52 
were subjected to midline fluid percussion injury (mFPI), 14 were 
used as sham-injured controls, and 24 rats were used as naïve 
controls. Forty animals were used for a 48-h survival time-point 
post-injury, and 50 animals were used for a 15-day survival study. 
The number of animals in each group and time point is shown 
in Table 1.
animal surgery
Following induction of anesthesia with 4.5% isoflurane in air for 
3 min, the animals were moved to a stereotaxic frame and kept 
anesthetized using a nose cone with a mixture of nitrous oxide/
oxygen (70/30%) and isoflurane (1.4%). Core body tempera-
ture was maintained at 37 ± 0.5°C using a rectal thermometer 
coupled to an automatically regulated heating pad (CMA150, 
CMA, Stockholm, Sweden). The scalp was opened by a midline 
incision after application of bupivacaine. The mFPI brain injury 
model was used according to previously used protocols (22, 23). 
In brief, a 4-mm circular craniotomy was performed over the 
midline 2 mm behind the bregma suture. An anchoring screw 
was attached to the skull bone, the trauma cap attached to the 
bone using tissue adhesive (Histoacrylic, Braun Aesculap AG, 
Tuttlingen, Germany), and dental cement (Dentalon; Hureaeus 
Kulzer, Hanu, Germany) was poured over the skull and allowed 
to set. The animal was moved to the FPI-device, the piston 
was released, and TBI was induced, delivering a pressure of 
2.20 ±  0.12  atm. The duration of apnea was recorded and the 
animal was allowed to stabilize its breathing pattern before being 
reattached to the stereotaxic frame. The trauma cap and dental 
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cement was removed, the bone piece replaced and secured with 
tissue adhesive. The scalp was sutured and the animal allowed to 
recover in a heated cage. Sham-injured controls were subjected 
to the entire surgical procedure except that the piston was not 
released. At 48 h or 15 days post-mFPI or sham injury, the rats 
were over-anesthetized using an i.p. injection of sodium pento-
barbital (0.5 ml of Euthasol®, 400 mg/l pentobarbital), and the 
brains removed for determination of BWC or tissue analysis (see 
below).
Treatment
To balance for individual cognitive performance, we divided the 
animals according to ability to learn to locate the hidden platform 
in the MWM prior to the injury into the different groups with 
similar MWM learning latencies (the short-term study). For 
both studies, AF16 or Scrambled peptides were prepared in vials 
labeled A or B by a researcher not involved in the study and una-
ware of the study design, where the code was not revealed until 
the completion of the study. In the long-term study, to balance 
the treatments groups of brain-injured animals in terms of injury 
severity, we used the apnea time to create groups with similar 
apnea times. The naïve animals were randomly assigned to either 
treatment A or B.
The treatment peptide AF16 or the scrambled inactive peptide 
(hereafter named Scramble) were instilled intranasally by briefly 
sedating the rats with isoflurane (4% in air for induction and 1% 
in air through a nosecone for maintaining sedation) and gently 
injecting 25 µl per nostril of isotonic saline solution with scram-
ble or AF-16 peptide (2 mg/ml), as previously described (15, 16). 
The first treatment was administered 30 min after mFPI or sham 
injury and at a corresponding time point for naïve animals. At 
6 h after the first administration of AF-16 or scramble peptide, an 
additional dose was given and then twice the following day for the 
48-h survival animals and twice daily for the following 3 days for 
the animals with 15 days survival after surgery. Several previous 
studies showed that the scramble peptide is inert, and also that 
AF-16 is without adverse events in naïve animals (15, 24). In 
addition, no influence on ICP nor other physiological parameters 
were observed in sham-exposed animals (15, 24). Since animal 
ethics regulation requires that animal number should be reduced 
whenever possible and without compromising scientific value, 
we, therefore, chose to omit an AF-16 -treated, sham-injured 
group since the study design also included an AF-16-treated 
naïve group.
Brain Water content
Immediately following sacrifice, the brain was rapidly removed 
from the cranium and cut into three coronal tissue samples of 
equal size. The most anterior sample was frontal to the impact/
craniotomy site and was discarded from further analysis. Each 
tissue sample was placed on pre-weighed sheets of aluminum 
foil that was weighed immediately following removal to obtain 
the wet weight (WW). Each tissue sample was then dried in 
a pre-heated oven at 80°C for 72 h and weighed once more to 
obtain dry weight (DW). Water content was calculated as a per-
centage of WW according to the formula % brain water content 
(BWC) = (WW − DW)/WW × 100.
Morris Water Maze
Using the MWM paradigm as previously described (25, 26), 
spatial learning and memory was evaluated. The MWM consists 
of a 1.4-m diameter circular tank and a 10-cm diameter white 
platform, placed in the southwest quadrant of the tank and sub-
merged 1 cm below the surface of the 28°C water. Simple visual 
cues to aid navigation were placed on roller curtains surrounding 
the pool.
Each swim trial was run by placing the rat in the tank at one 
of four designated entry points (W, N, E, and S) facing the wall, 
activating the video-based computer tracking system (HVS 
Image Ltd., Buckingham, UK), and the trial was terminated 
when the rat located the platform. The rat was allowed to remain 
undisturbed on the platform for 15 s to acquire the visual cues 
surrounding the pool. If the animal failed to locate the platform 
within 120 s, it was placed on the platform for 15 s. Each learn-
ing trial was analyzed for latency to locate the hidden platform, 
distance swum, and swim speed.
The animals with 48 h survival time were trained prior to sham 
injury or mFPI using four learning trials per day with 30  min 
rest interval between trials for 2 days before TBI and subjected 
to the memory test (probe trial) at 48 h post-injury. The rats with 
15 days survival were evaluated for learning ability in the MWM 
using four learning trials per day for 4 days (day 9 to 12 after TBI) 
followed by the memory (probe) trial test at day 15 after TBI. In 
the memory (probe) trial test, the platform was removed and the 
trial was analyzed for latency to find the platform site, number 
of crosses over the platform site, and time spent in the correct 
quadrant of the pool.
hemispheric and Ventricle Volumes
Rats sacrificed 15 days after mFPI or sham injury were transcardi-
ally perfused with isotonic saline followed by phosphate-buffered 
4% formaldehyde (Histolab AB, Gothenburg, Sweden). Following 
rapid removal, the brain was placed in 4% formaldehyde in 
phosphate-buffered saline (PBS) at 4°C for 24 h and then in 30% 
w/v sucrose at 4°C for 72 h. It was then snap-frozen in isopentane 
(Sigma, Stockholm, Sweden) at -55°C. Sections were made in a 
cryostat (HM500; Microm, Walldorf, Germany) at −22°C.
Nine coronal sections from bregma levels 0 to −5 mm, approx-
imately 0.5  mm apart, were stained with Mayer’s Hematoxylin 
and Eosin (Histolab) and, using a digital camera (Olympus), 
photographed in a stereomicroscope (Zeiss Stemi 2000-C; Zeiss 
Gmbh, Göttingen, Germany). The hemispherical volume and 
cortical lesion volume were calculated using the Sectiontovolume 
software according to a previously published protocol (27).
immunohistochemistry
Four primary antibodies (Table 2) were used to characterize the 
brain injury morphologically and compare it to the brains of sham-
injured and naïve controls. Frozen sections on SuperFrost+ slides 
were thawed for 5 min before being placed into chilled acetone 
for 1 min of post-fixation. The sections were washed for 5 min in 
0.1 M PBS. Endogenous peroxidation was blocked using the solu-
tion provided in the MACH-1 kit (Biocare Medical, Concord, CA, 
USA) for 5 min. The sections were then washed for 5 min in PBS. 
Cross-reactive protein binding was blocked using the solution 
TaBle 2 | Primary antibodies used for immunohistochemical evaluation.
antibody Target Manufacturer Dilution used in 
experiments
MAP2 (M9942) Neuron (somas and 
dendrites)
Sigma 1:500
GFAP (M0761) Reactive astrocytes Dako 1:200
Beta-APP 
(51-2700)
Axonal deposits Life technologies 1:200
Olig2 (AB9610) Mature and immature 
oligodendrocytes
MerckMillipore 1:500
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provided in the MACH-1 kit for 15  min. Excess protein block 
was tapped off, the primary antibody was applied to the sections 
and incubated overnight in 4°C. The sections were then washed 
three times in PBS before the probe provided in the MACH-1 kit 
was applied and incubated for 15 min. The sections were washed 
three times for 5 min in PBS. The HRP polymer provided in the 
MACH-1 kit was applied and incubated for 30 min. The sections 
were washed three times for 5 min in PBS. As chromogen, the 
diamino-benzidine (DAB) solution supplied in the MACH-1 
kit was used and applied for 5 min before rinsing in deionized 
water for 5 min. The sections were counterstained by a brief dip in 
Mayer’s hematoxylin (Histolab, Gothenburg, Sweden), followed 
by rinsing in deionized water for 5 min. The sections were dried in 
an alcohol to xylen ladder before coverslips were mounted using 
Pertex (Histolab). In negative controls, the same protocol was run 
except that the primary antibody was omitted.
Different regions of interest (ROI) from four stained sections 
from bregma −1.0 to −3.0 mm were photographed at 100× mag-
nification using light microscopy (Zeiss Axiovision, Zeiss Gmbh) 
resulting in micrographs in the size of 1.39 mm × 1.04 mm. The 
micrographs were analyzed using the Zen software (Zeiss Gmbh) 
to measure the area positively stained for GFAP in the hilus of the 
dentate gyrus (HDG) and CA3 of the hippocampus. The thresh-
olds for positive staining was manually set by defining a region 
positive for GFAP, and this threshold was then automatically 
applied by the software on all sections throughout the analysis. 
The CA3 area with loss of MAP2 staining was manually outlined 
for each section, where only an area with clearly reduced stain-
ing compared to neighboring, intact tissue was included in the 
analysis. The number of MAP2-positive cells with pyknotic cell 
nuclei in the CA3 region was manually and exhaustively counted. 
For the β-APP and Olig2 analyses, the ROIs were in the white 
matter tracts of the corpus callosum, external capsule, cingulate 
gyrus and the striatum, and the number of positive deposits or 
cells, respectively, were manually and exhaustively counted. The 
average number per ROI was statistically analyzed.
statistics
All data were sampled and entered at time of the experiments 
whenever possible and handled in Microsoft Excel (Microsoft, 
Redmond, WA, USA) before it was evaluated using Statistica 
(Statsoft, Tulsa, OK, USA). The data for the different experi-
ments were tested for normal distribution using Shapiro–Wilk’s 
test. If the data were normally distributed, a one-tailed two way 
ANOVA for injury and treatment was performed. If the data 
were not normally distributed, a non-parametric one way and 
one-tailed ANOVA using Kruskal–Wallis test was used and fol-
lowed by Mann–Whitney tests between parameters. A p-value of 
below 0.05 was considered significant. Parametric statistics were 
used for weight, lesion volume, MWM, and BWC analyses while 
non-parametric tests were used for the immunohistochemistry 
analyses.
resUlTs
surgery
In the short-term study with 48 h post-injury survival time, three 
out of 20 animals died in the immediate post-operative period 
resulting in a 15% acute mortality. The mean post-traumatic 
apnea was 38.6 ± 4.6 s for the animals treated with the inactive, 
scrambled peptide and 40.0 ±  2.9  s for AF16-treated animals. 
A significant weight loss was induced by the brain injury when 
compared to sham-injured controls (p < 0.05) although it was not 
influenced by the treatment compound (Figure 1A).
In the long-term study with 15 days post-injury survival time, 
5 out of 32 animals died in the immediate post-operative period 
resulting in a 16% acute mortality rate. There was no difference 
in apnea time between scramble-treated (32.3 ± 3.2 s) and AF16-
treated animals (33.9 ± 3.2 s). The brain injury induced a peak 
10% weight loss at 4 days post-injury (Figure 1B). At 15 days post-
injury, the brain-injured animals had significantly lower weight 
than sham-injured and naïve animals (p < 0.05, Figure 1B), not 
influenced by the treatment compounds.
short-term study—48 h survival
The primary endpoints in the short-term study using a 48-h post-
injury survival were BWC and memory retention in the MWM.
Brain Water Content
The diffuse brain injury model (mFPI) used in the present report 
altered the BWC modestly after 48 h when compared to naïve or 
sham-injured animals (Figure 2). The differences in BWC between 
groups were small in the two samples obtained from beneath the 
impact site. In the caudal region, the animals subjected to TBI 
and treated with scramble peptide had significantly (p <  0.05; 
Figure  2B) higher BWC (78.62 ±  0.56%) compared to naïve 
scramble-treated animals (78.22 ± 0.23%), naïve AF-16-treated 
animals (78.31 ± 0.22%), and AF16-treated animals subjected to 
mFPI (78.27 ±  0.27%), but not sham-injured scramble-treated 
animals (78.37 ± 0.35%). Thus, treatment with AF-16 attenuated 
the increased BWC in brain-injured animals.
Memory Test in MWM
The animals were trained in the MWM for 2 days prior to the 
injury. On the second day of pre-training the mean latency to 
find the platform was 22.6 ± 1.1 s over all four trials. The ani-
mals were then randomized in order to get balanced treatment 
groups.
The brain-injured animals swam longer and faster than 
the sham- and uninjured controls (p < 0.05; data not shown), 
though no difference in latency to find the platform area or 
time spent in the correct quadrant were found (Figures 3A,B). 
AF16 did not alter the performance in the MWM probe trial 
FigUre 1 | Post-injury weight changes (means ± seM). (a) Weight changes in the 48-h survival study. A significant weight loss in brain-injured animals was 
observed compared to sham-injured and naive animals (indicated with an asterisk, p < 0.05) at post-injury day 1 and 2. Treatment with antisecretory factor (AF)-16 
or the inactive control (scramble) did not influence post-injury weight loss. (B) Weight changes in the long-term study. A persistent weight loss in brain-injured 
animals compared to sham-injured and naive controls were observed (indicated with an asterisk, p < 0.05) that was not influenced by AF-16 or the inactive control 
(scramble) treatment.
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compared to scramble treatment in either naïve or brain-
injured animals.
long-term study, 9–15 Day survival
Learning Trials at Post-Injury Day 9–12 in the MWM
Rats subjected to mFPI had significantly longer latency 
(Figure  3A) to find the platform and longer swim distance 
(Figure 3B) compared to sham-injured and naive animals in all 4 
trial days. No differences were found in swim speed between any 
of the treatment groups (Figure 3C).
Antisecretory factor-16 treatment did not influence any of 
the MWM parameters in uninjured (sham  +  naïve) animals 
(Figures 3A–C). AF-16-treated, brain-injured rats had a shorter 
latency to locate the hidden platform (p < 0.05; Figure 3A) and 
a shorter swim distance (p < 0.05; Figure 3B) on day 2 of the 
MWM learning trials than scramble-treated, brain-injured rats.
Memory (Probe) Trial Test in the MWM, Day 15 
Post-Injury
Rats subjected to mFPI had significantly longer latency to enter 
the platform area compared to both sham- injured and naive 
animals (p <  0.05; Figure  3D). Naïve animals swam over the 
area originally harboring the platform significantly more times 
than both brain-injured and sham-injured animals (p <  0.05; 
Figure 3E).
AF-16 treatment did not influence the results of the probe 
trial in uninjured animals. In brain-injured rats, AF-16-treated 
had a similar latency to locate the platform area when com-
pared to the scramble-treated, brain-injured rats (p  =  0.23; 
Figure  3D). Scramble-treated, brain-injured animals spent 
significantly less times in the correct platform quadrant when 
compared to the uninjured groups (p  <  0.05; Figure  3F). 
Brain-injured animals treated with AF-16 had more time in 
the correct platform area compared to brain-injured, scramble-
treated animals (p < 0.05; Figure 3F).
Brain Tissue and Ventricular Volume
The volumetric analyses did not show any significant difference in 
brain tissue or lateral ventricular volume at 15 days between any 
of the treatment groups (Figures 4A,B).
Immunohistochemistry
Compared to sham- and uninjured controls, brain injury using 
the mFPI model resulted in an increased number β-APP deposi-
tions in the white matter (Figure 5), which were not influenced 
by treatment with either AF-16 or scramble peptide (Figure 5G).
GFAP was used to analyze the HDG region of the hippocam-
pus, where brain injury resulted in an increased GFAP stain-
ing compared to the sham- and uninjured animals (p <  0.05; 
Figure  6). Treatment with AF16 showed less GFAP staining 
although without reaching statistical significance (p  =  0.11; 
Figure  5A) compared to scramble-treated, brain-injured 
animals.
Using MAP2 staining, we measured the unstained area and 
counted the number of pyknotic nuclei in the CA3 region of the 
hippocampus. Compared to sham- and uninjured controls, the 
brain injury resulted in an increased area without MAP2 staining 
which was not influenced by AF-16 treatment (data not shown). 
Brain injury also resulted in an increased number of pyknotic 
cells which was not influenced by AF-16 or scramble treatment 
(Figure 7).
The immunostaining for Olig2 was used to assess oligoden-
drocyte and their progenitor cells in selected white matter tracts 
at 15 days post-injury. No difference was found in the number of 
Olig2-positive cells between the treatment groups in any of the 
areas analyzed (Figure 8).
DiscUssiOn
The present study provides evidence that intranasal administra-
tion of the antisecretory peptide AF-16 attenuates the TBI-induced 
FigUre 2 | (a) Brain water content (BWC) (means ± SEM) at 48 h post-injury in naïve animals, sham-injured controls and animals subjected to the midline fluid 
percussion brain injury (mFPI) treated with active compound [antisecretory factor (AF)-16] or inactive control substance (scramble). The brain regions underlying the 
impact were split into two halves. In the caudal brain regions, the mFPI induced a significant (*) increase in BWC compared to all other groups, except the 
sham-injured scramble-treated group (p = 0.11). Treatment with AF-16 following mFPI attenuated the increase in BWC compared to brain-injured, scramble-treated 
group (#p < 0.05). (B,c) Memory (probe) trial performed 48 h after sham- or midline fluid percussion injury (mFPI) and in naïve controls. Graphs showing the results 
from the first 30 s of the memory test in the short-term experiments (means ± SEM). The animals were treated with intranasal administration of either active 
compound (AF-16) or inactive control substance (Scramble). The latency to locate the platform area did not differ among the different treatment groups (B), neither 
did the time spent in the platform quadrant (c).
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brain edema compared to an inactive reference scramble peptide 
in brain-injured rats at 48  h post-injury. In addition, in the 
15-days survival animals the latency to find the hidden platform 
in the MWM test during the learning trials was shortened by 
AF-16 treatment, indicating attenuated cognitive deficits by 
AF-16 administration post-TBI. However, there were no signifi-
cant effects by AF-16 on brain tissue volume or on the memory 
tests and no immunohistochemical correlates to the observed 
improvements in edema and learning abilities were observed. 
Our results suggest that AF-16 exerts additional pharmacologi-
cal actions than merely the edema-reducing capacity in order to 
explain the observed improvements in cognitive function. Such 
additional mechanisms may include, e.g., immunoregulatory 
functions of the compound (17).
In the present study, we used the intranasal route for the 
delivery of the peptide AF-16 aiming to gain access to the 
brain parenchyma and CSF. Pathways for the delivery of drugs, 
such as peptides and proteins to the brain from the blood are 
efficiently restricted by the blood–brain barrier (28). However, 
several compounds have been found to bypass the BBB using 
the olfactory nerve. High molecular weight proteins, such as 
horseradish peroxidase, and peptides, such as insulin-like 
growth factor I (IGF-I) and insulin, have been conclusively 
observed to be taken up after nasal instillation, transported 
to the olfactory bulb and then further throughout the brain 
including into the CSF (29–32). The peptide AF-16 used in 
the present report reaches high concentration in the CSF after 
intranasal instillation (16) and the beneficial effects imply that 
FigUre 3 | results from the Morris Water Maze learning trials (a–c) and memory (probe) trial (D–F) for the 15-day survival study (means ± seM). 
Rats were subjected to sham- or midline fluid percussion injury (mFPI), and naïve controls were used. The animals were treated with either antisecretory factor 
(AF)-16 as the active, treatment compound or an inactive control compound (scramble). There was a clear effect on both latency (a) and path length (B) by the 
brain injury, without influencing the swim speed (c) with the exception of sham-injured, scramble-treated animals that swam significantly slower than all other 
treatment groups on the fourth day of the trials [p < 0.05, (c)]. AF-16 treatment significantly decreased the latency to find the platform and path length on the 
second day of the learning trials compared to scramble-treated, brain-injured controls [p < 0.05, (a,B)]. The memory (probe) trial at 72 h following the last learning 
trial showed that scramble-treated, brain-injured animals had significantly longer latency to find the platform area than the naïve and sham-injured treatment groups 
[p < 0.05, (D)]. Both naïve treatment groups had significantly more passes through the platform area than sham operated or injured groups [p < 0.05, (e)]. 
Scramble-treated, brain-injured animals spent significantly less time in the correct quadrant compared to all other groups [p < 0.05, (F)]. Treatment with AF-16 in 
brain-injured animals did not significantly reduce the latency to reach the area originally harboring the hidden platform [p = 0.23, (D)], increase the passes (e), or 
increase the time spent in the platform area (F).
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FigUre 4 | hemispheric volumes for left and right hemispheres, showing no statistically significant differences between any of the treatment groups 
(a). Figure (B) shows an example of the technique used to estimate tissue volume, using nine sections from a mouse subjected to midline fluid percussion injury 
(mFPI) and treated with the inactive compound (scramble).
8
Clausen et al. AF-16 Reduces Edema and Improves Cognitive Function Following Diffuse TBI in Rats
Frontiers in Neurology | www.frontiersin.org February 2017 | Volume 8 | Article 39
AF-16 reached the brain parenchyma and retained its biological 
activity after the intranasal instillation also in the present study. 
These results are in agreement with those achieved in previous 
studies where intranasal administration of AF-16 attenuated 
the rise in ICP and reduced the high mortality in herpes sim-
plex type I encephalitis in rats (18). Further, the elevated ICP 
developing after a cryogenic brain lesion to rats was lowered 
by intranasal AF-16 (15, 16). The beneficial effects achieved 
by intranasal AF-16 administration in the present study argue 
that the study drug enters the injured brain after mFPI. An 
advantage of the nasal administration for AF-16 administration 
is that it is non-invasive, acts rapidly and can be given to almost 
every TBI patient, even at prehospital situation as well as in 
children (33–35).
We used MWM performance (short-term study) and apnea 
time (long-term study) to enable us to get equal experimental 
brain-injured groups in terms of mFPI impact. In the experi-
mental setting, a transient TBI-induced weight loss is common 
and reflects injury severity (23, 36). Thus, the midline FPI 
(mFPI) model of diffuse TBI model used in the present report 
resulted in a decreased body weight in the first post-injury phase 
which was not influenced by AF-16 treatment. The mFPI model 
resulted in a 15% mortality and a 35-s apnea time, consistent 
with a mild–moderate mFPI (37, 38). The mFPI model results 
in wide-spread axonal injury as well as neuronal loss in, e.g., 
the hippocampus and thalamus (39–41). In our hands, the mFPI 
used in the present study caused limited structural injuries and 
no hemorrhages (23), again consistent with a mild–moderate 
TBI. However, edema formation has previously been less exhaus-
tively characterized in this TBI model. In early reports using 
magnetic resonance imaging 2 and 90 days after mFPI in rats, 
minor edema in the corpus callosum was observed at 2  days 
after injury (42). In addition, the vascular reactivity reached the 
highest level at 24 h after injury (43), suggesting an acute effect 
of the trauma on the gross morphology of the vascular system 
of the brain in this TBI model. Here, the mFPI model resulted 
in an increase in BWC which was significantly attenuated by 
AF-16 treatment. This post-traumatic increase in BWC elicited 
by mFPI was modest compared to more focal TBI models such 
as the lateral FPI model where the BWC increased from 75 to 
82% water (44), similar to the BWC increase in the controlled 
cortical impact model (45, 46).
In previous experimental studies on rats, AF-16 significantly 
reduced the brain edema after a cold lesion, as determined by 
the counteraction of the lesion-induced elevation of ICP (15, 
16). Increased ICP in experimental diffuse TBI models may lead 
to neuronal impairment and neuronal death (47). Although the 
role for increased BWC in axonal injury has not been firmly 
established, increased ICP is observed in a subset of patients 
with severe diffuse injury (48, 49). Thus, the attenuation of post-
traumatic increase in BWC observed in the present report is likely 
beneficial.
One of the most devastating consequences of clinical TBI, 
regardless of severity, is cognitive impairment. Thus, attenu-
ation of cognitive impairment is a key target in the search for 
novel pharmaceutical targets in experimental TBI research. 
We observed no effect on memory function by AF-16 at 48  h 
post-injury; in contrast, the TBI-induced learning deficits were 
attenuated and memory was improved by AF-16 treatment in 
the 15-day survival groups. The swim speed data argue that the 
prolonged latencies to the hidden platform in the MWM are not 
caused by TBI-induced motor deficits. Additional behavioral 
tests (50) are needed to establish any effects of AF-16 on more 
complex fine motor tasks and/or balance function.
The link between post-traumatic brain edema and func-
tional outcome has not been firmly established, but the present 
and previously published results suggest a beneficial effect by 
decreasing edema on cognition. Post-injury treatment of rats 
with the sulphoraphane, a plant substance shown to decrease 
cerebral edema, improved the performance in the MWM on 
FigUre 5 | continued
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FigUre 6 | immunohistochemistry for glial fibrillary acidic protein (gFaP), an astrocytic marker of the glial scar, in the hilus of the dentate gyrus of 
the hippocampus at 15 days post-injury. (a) The area of GFAP immunostaining was larger in brain-injured animals (p < 0.05). Although the area stained with 
GFAP was smaller in AF-16-treated, brain-injured animals compared to that of brain-injured, control (scramble)-treated animals it did not reach statistical significance 
(p = 0.107). (B–F) Representative examples from sham-injured (B), naïve (c–D), and animals subjected to midline fluid percussion injury (mFPI).
FigUre 5 | continued 
immunohistochemistry for beta-amyloid precursor protein (β-aPP), a marker for axonal injury, in the corpus callosum at 15 days post-injury. In left 
panel (a,c,e), 200× magnification images of animals subjected to midline fluid percussion injury (mFPI, A and C) compared to naïve controls (e) are shown. In the 
right panel (B,D,F), images using 200× magnification are shown. (a–F) β-APP deposits indicated by arrows. (g) In all regions of interest, a marked injury effect was 
found (*p < 0.05) although the number of β-APP deposits was not influenced by treatment with antisecretory factor-16 or scramble treatment. Str, striatum; CE, 
external capsule; CC, corpus callosum; CG, cingulate gyrus.
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both learning and memory (51). After TBI in juvenile rats, 
reduction of edema using siRNA for aquaporin 4 resulted in 
an improved outcome on learning and neuromotor function 
(52). In a weight drop model of diffuse TBI in mice, a robust 
treatment effect on BWC and a corresponding improvement 
in neuromotor function by minocycline was found (53). 
In contrast, edema-reducing effects of estrogen sulfate and 
glibenclamide did not translate into improved functional 
outcome (54, 55).
Since the improved MWM performance up to 15-days 
post-injury may not be explained solely by the edema-reducing 
functions of AF-16 at 48 h post-injury, we then searched for other 
potential mechanisms using histology.
There was no loss of brain tissue at 15-days after mFPI, 
confirming our findings from previous work in mice (19) and 
in rats (56). Although severe diffuse clinical TBI produces a 
progressive atrophy of the injured white matter tracts (57), it 
is plausible that at the injury severity used in the present study 
caused insufficient injury to produce a significant loss of brain 
tissue in the 2-week observation period. Instead, we searched 
for immunohistochemical markers that could correlate to the 
observed cognitive improvement. The immunohistochemical 
FigUre 7 | immunohistochemistry evaluating the number of (a) pyknotic nuclei in the ca3 of the hippocampus at 15 days post-injury, showing an 
increased number of pyknotic cells in brain-injured animals compared to sham- and naïve controls (*p < 0.05, Figure 8). AF-16-treated animals had 
similar cell counts as scramble-treated controls, regardless of injury status (Figure 8). (B–D) Representative examples from a naïve animals (B) and brain-injured 
animals (c,D) subjected to midline fluid percussion injury (mFPI) and treated with inactive control, scramble, compound (c), or the active compound AF-16 (D).
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FigUre 8 | The number of Olig2-positive cells at 15 days post-injury in selected brain regions of interest following traumatic brain injury using the 
midline fluid percussion injury (mFPi) model. The number of Olig2-positive cells were not altered by the injury or by treatment with active (AF-16) or inactive 
(scramble) compound. Str, striatum; CE, external capsule; CC, corpus callosum; CG, cingulate gyrus.
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markers were chosen to investigate axonal injury [β-APP (19, 
58)], white matter oligodendrocytes [Olig2 (23)] as well as hip-
pocampal astrogliosis [GFAP (59, 60)] and injury to neuronal 
cells and dendrites [MAP2 (61, 62)].
We observed a markedly increased number of bilateral β-APP 
deposits in white matter tracts post-injury. While the mFPI 
resulted in a bilateral increase in deposits β-APP, the numbers 
were similar in the AF-16 and scramble-treated groups. In the 
evaluated hippocampi, there was reactive astrogliosis in the den-
tate gyrus of the hippocampus after injury as well as an increased 
number of pyknotic cell nuclei and loss of MAP2 staining in the 
hippocampal CA3 region. Persistent astrogliosis was observed 
by others following mFPI in the dentate gyrus and CA1 areas 
of the hippocampus (63), although no difference in the number 
of astrocytes was observed in another study (64). Here, the hip-
pocampal astrogliosis was not significantly attenuated by AF-16 
treatment in brain-injured animals (p = 0.11), although we suggest 
that the observed trend is sufficiently interesting for evaluation 
at additional post-injury time-points in future studies. Neuronal 
cell loss in the CA3 of the hippocampus was found to correlate to 
MWM deficits following mFPI (65), a finding not confirmed in 
our study. In contrast to our previous study using a shorter sur-
vival time-point (23), we did not observe a TBI-induced change 
in Olig2-positive cells which may be related to the evaluated time 
point and the injury severity in this study. In the present study, 
we focused on brain edema, cognitive evaluation, and histologi-
cal markers. The alterations induced by the injury and/or AF-16 
treatment could in additional studies also focus on markers of 
brain edema such as MMP-9 (66) and neuroinflammation (67) 
using additional animal groups and time points.
We conclude that we could not identify a single causative 
histopathological outcome measures explaining the improved 
functional outcome by AF-16 treatment. It is plausible that the 
mechanisms are multifactorial although our data may imply that 
attenuation of hippocampal astrogliosis, plausibly to a higher 
degree than the effects on the white matter pathology, may be a 
contributing mechanism.
At the chosen injury severity of the mFPI model, there were 
no hemorrhages, marked destruction of brain parenchyma, or 
profound behavioral defects. In clinical practice, most sequelae 
of mild TBI or brain concussion are associated with white 
matter pathology including axonal injuries (68). In this TBI 
model, injury severity needs to be markedly increased to 
increase BWC. However, one important limitation with the 
mFPI model is that animal mortality increases substantially 
when injury severity is increased. Since BWC was only one 
of several read-outs in this study, our findings point to other 
mechanisms of action for AF-16. To study the effect of AF-16 
on BWC in TBI, other injury models such as the lateral FPI 
could be used in future studies, since brain edema is more 
extensive in this injury model (55, 69).
In the present study, only the 2 mg/kg concentration of AF-16 
was used which was instilled intranasally twice daily for 2 or 
5  days, depending on scheduled post-traumatic survival time. 
Although a lower AF-16 dose was previously used (18, 24), we 
chose the 2  mg/kg dose based on effective ICP reductions in 
cryogenic brain injury with this dosing regimen (16). A recent 
report indicates that maximal concentrations in the CSF is 
achieved after about 30 min, and thereafter declines (16). Further 
studies are required to map the optimal dose and administration 
regimes required to achieve the optimal treatment effects and 
brain concentrations. It is important to stress that no adverse 
side effects by AF-16 were noticed by the selected dose and 
administration route used here. We also used the MWM as 
our cognitive test and additional tests, evaluating more com-
plex behavioral changes (19), were not included. To establish 
a definitive role for AF-16 in TBI, this treatment needs evaluation 
using additional time windows, focal TBI models, and extended 
behavioral testing. The promising effects observed in the present 
study using a clinically relevant route of administration in a 
diffuse brain injury model warrants further study of AF-16 as 
a treatment option for TBI.
cOnclUsiOn
We used an experimental model system of diffuse TBI, midline 
fluid percussion injury (mFPI), in rats to investigate if intranasal 
administration of a synthetic peptide with antisecretory activity, 
named AF-16, had any neuroprotective effects. A scrambled, 
inactive reference peptide was used as a control. At 48  h after 
mTBI the induced brain edema was significantly counteracted by 
intranasal instillation of the peptide AF-16 without altering the 
performance on the memory test in the MWM. In contrast, after 
15 days post-injury treatment using AF-16 significantly attenu-
ated the learning deficits in the MWM. No neuroprotective effects 
could, however, be demonstrated on the histological outcome 
measures by AF-16 treatment. We conclude that post-injury 
intranasal administration of the peptide AF-16 attenuates early 
post-traumatic brain edema and attenuates the cognitive deficits 
observed at 2 weeks following diffuse TBI in rats. The study of this 
clinically relevant route of administration of AF-16 is warranted 
also in other TBI models.
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